[Microbiological, kinetic and clinical study on a new cephamycin: cefotetan].
Microbiological, kinetic and clinical studies were conducted on a new cephamycin, cephotetan. In vitro the antibiotic was found to be very effective against all strains tested. It had a particularly strong action against Gram negative bacteria too. Kinetically speaking, an intravenous bolus produced a high plasmatic concentration with a half life of about 4 hours. Elimination via the kidneys was fastest in the first 3 hours after administration (49.82%) and the slowed down. 82.76% of the dose administered was excreted within 24 hours. This antibiotics is particularly indicated in cases of urinary, respiratory and biliary infections.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001996:Bronchopneumonia / Q000188:drug therapy; D015313:Cefotetan; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000378:metabolism / Q000627:therapeutic use* / Q000652:urine; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D006207:Half-Life; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D002513:Cephamycins; D015313:Cefotetan
Ricerca microbiologica, cinetica e clinica su una nuova cefamicina: cefotetan.